The pharmaceutical market for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD), has the potential to become lucrative owing to the current lack of approved agents and the disease’s large and growing prevalence. The body of evidence for the significant burden the disease places on healthcare systems is accumulating, particularly with respect to the increased risk of cardiovascular disease, liver failure, and NASH’s potential to quickly become the leading reason for liver transplantation. The lack of treatment options, the limited awareness of the disease, and its complications have kept diagnosis and treatment rates low. Despite guidelines recommending certain off-label medications, prescribing is usually limited to specialists caring for patients with more-advanced disease. However, as education increases, novel diagnostic tools are developed, and approved medical therapies become available, diagnosis and treatment rates will increase and drive growth of the market overall. Over the 2019-2029 study period, the NASH market will see the launches of the first therapies from a rich pipeline of emerging therapies, which will fuel an exponential market expansion.
- What is the prevalence of NASH, and what is driving the growth of this indication?
- How is NASH being managed? With no approved medications, how are physicians using available prescription medications off-label to treat the disease?
- Which emerging therapy will gain the greatest share in the nascent branded therapy market?
- Where will Intercept’s obeticholic acid, Madrigal’s resmetirom, Allergan’s cenicriviroc, and Novo Nordisk's semaglutide fit into the evolving NASH treatment paradigm?
United States, France, Germany, Italy, Spain, United Kingdom, Japan
Key companies mentioned:
Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Allergan, Inventiva Pharma, Galectin Therapeutics, Galmed Pharmaceuticals, Viking Therapeutics, Cirius Therapeutics, NGM Bio, Novo Nordisk, Novartis, Gilead, Bristol-Myers Squibb, Enanta Pharmaceuticals
Key drugs covered:
Obeticholic acid, resmetirom (MGL-3196), cenicriviroc, belapectin (GR-MD-02), aramchol, VK-2809, MSDC-0602K, pegbelfermin (BMS-986036), aldafermin (NGM282), efruxifermin (akr-001), EDP-305, semaglutide, lanifibranor, tropifexor, cilofexor, firsocostat, vitamin E, pioglitazone
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.